Korro Bio: First cohort dosed in Phase 1/2 clinical trial for KRRO-121
Korro Bio has dosed the first cohort in its Phase 1/2 clinical trial (Anchor) for KRRO-121. Dosing in UCD patients is expected to start in H1 2027, with an interim readout in H2 2027.
: Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121 Korro Bio - Dosing In Ucd Patients Expected To Start In H1 2027; Interim Readout In H2 2027 Source text:... com;)